title: Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database.
authors.forename: M
authors.initials: M
authors.lastname: Ostergaard
authors.forename: J
authors.initials: J
authors.lastname: Unkerskov
authors.forename: L
authors.initials: L
authors.lastname: Linde
authors.forename: N S
authors.initials: NS
authors.lastname: Krogh
authors.forename: T
authors.initials: T
authors.lastname: Ravn
authors.forename: V S
authors.initials: VS
authors.lastname: Ringsdal
authors.forename: A
authors.initials: A
authors.lastname: Petri
authors.forename: L S
authors.initials: LS
authors.lastname: Andersen
authors.forename: U
authors.initials: U
authors.lastname: Tarp
authors.forename: A
authors.initials: A
authors.lastname: Hansen
authors.forename: E
authors.initials: E
authors.lastname: Hjardem
authors.forename: M L
authors.initials: ML
authors.lastname: Hetland
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003718:Denmark; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D000069285:Infliximab; D053208:Kaplan-Meier Estimate; D008727:Methotrexate / Q000627:therapeutic use; D010349:Patient Compliance; D011358:Product Surveillance, Postmarketing; D011446:Prospective Studies; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012042:Registries / Q000706:statistics & numerical data*; D012074:Remission Induction; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept; D008727:Methotrexate